Q2 2025

Filed Aug 14, 2025 · 10-Q · 45 days after period end · 0001477932-25-005887

Q2 2025 · 10-Q

Revenue

$117.00K

— vs Q2 2024

Net Income

-$811.00K

N/M vs Q2 2024

EPS Diluted

-$0.01

N/M vs Q2 2024

Gross Profit$79,000—

Operating Income

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$117.00K	$0.00	$44.00K	$5.00K
Net Income	-$811.00K	-$709.00K	-$1.56M	-$926.00K
EPS Diluted	-$0.01	-$0.01	-$0.03	-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR